Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;77(1):5-18.
doi: 10.1007/s00280-015-2901-x. Epub 2015 Nov 20.

Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy

Affiliations
Review

Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy

Paola Perego et al. Cancer Chemother Pharmacol. 2016 Jan.

Abstract

Oxaliplatin is a third-generation platinum compound approved for clinical use relatively recently as compared to other drugs of the same class. Its main cellular target is DNA, where similarly to cisplatin and carboplatin it forms cross-links. However, due to a unique indication for colorectal cancer, synergistic interaction with fluoropyrimidines and peculiar toxicity profile, oxaliplatin is different from those compounds. Multiple lines of evidence indicate differences in transport and metabolism, consequences of DNA platination, as well as DNA repair and transduction of DNA damage. Here, we explore the preclinical features that may explain the unique properties of oxaliplatin in the clinics. Among them, the capability to accumulate in tumor cells via organic cation transporters, to kill KRAS mutant cells and to activate immunogenic cell death appears helpful to explain in part its clinical behavior. The continuous investigation of the molecular pharmacology of oxaliplatin is expected to provide clues to the definitions of predictors of drug activity and toxicity to translate to the clinical setting.

Keywords: DNA repair; Drug accumulation; Oxaliplatin; Personalized medicine; Survival pathways.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources